Exact Sciences (EXAS)
(Delayed Data from NSDQ)
$46.81 USD
-0.75 (-1.58%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $46.82 +0.01 (0.02%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EXAS 46.81 -0.75(-1.58%)
Will EXAS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for EXAS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EXAS
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
Why Is Exact Sciences (EXAS) Down 17.5% Since Last Earnings Report?
EXAS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Exact Sciences (EXAS) Witnesses Rising Expenses, Competition
Exact Sciences (EXAS) to Showcase Favorable Research Outcome
Other News for EXAS
Exact Sciences (EXAS) Receives a Buy from Piper Sandler
Peeling Back The Layers: Exploring Exact Sciences Through Analyst Insights
November 15th Options Now Available For EXACT Sciences (EXAS)
Exact Sciences schedules second quarter 2024 earnings call
Dynatrace initiated, U.S. Bancorp downgraded: Wall Street's top analyst calls